Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

著者: Bülent Görenek, Jeroen J. Bax, Giuseppe Boriani, Shih‐Ann Chen, Nikolaos Dagres, Taya V. Glotzer, Jeff S. Healey, Carsten W. Israel, Gulmira Kudaiberdieva, Lars‐Åke Levin, Gregory Y.H. Lip, David T. Martin, Ken Okumura, Jesper Hastrup Svendsen, Hung‐Fat Tse, Giovanni Luca Botto, ESC Scientific Document Group, Christian Sticherling, Cecilia Linde, Valentina Kutyifa, Robert Bernat, Daniel Scherr, Chu‐Pak Lau, Pedro Iturralde, Daniel P. Morin, Irina Savelieva, Gregory Y.H. Lip, Bulent Gorenek, Christian Sticherling, Laurent Fauchier, A. Goette, Werner Jung, Marc A. Vos, Michele Brignole, Christian Elsner, Gheorghe‐Andrei Dan, Francisco Marı́n, Giuseppe Boriani, Deirdre A. Lane, Carina Blomström Lundqvist, Irina Savelieva - EP Europace 2017 被引用: 240

Among atrial tachyarrhythmias (AT), atrial fibrillation (AF) is the most common sustained arrhythmia. Many patients with AT have no symptoms during brief or even extended periods of the arrhythmia, making detection in patients at risk for stroke challenging. Subclinical atrial tachyarrhythmia and asymptomatic or silent atrial tachyarrhythmia often precede the development of clinical AF. Clinical AF and subclinical atrial fibrillation (SCAF) are associated with an increased risk of thromboembolism. Indeed, in many cases, SCAF is discovered only after complications such as ischaemic stroke or congestive heart failure have occurred